This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1353 entries already.
Mediar Therapeutics (Cambridge, MA, USA), a company developing a portfolio of first-in-class therapies to treat fibrosis, announces a US$105m financing including a US$85m Series A co-led by Novartis Venture Fund […]
Paris-based AI-inspired drug discovery specialist Iktos SA has closed a 15.5m financing to expand its platform and kick-start the new CRO Iktos Robotics.
The eye disease specialist Oculis Holding AG has been listed on Nasdaq following the merger of Oculis SA with European Biotech Acquisition Corp.
Drug developer Confo Therapeutics and Eli Lilly & Company have inked a worldwide licensing agreement to co develop Confo’s neurophatic pain candidate CFTX-1554.
The fourth fund of High-Tech Gründerfonds has reached a final fund volume of 493.8m
British anti-aging therapeutics developer 5 Alarm Bio Ltd has raised £500K in a seed financing for testing its lead compound FAB001 for healing chronic wounds.
Interferon-gamma overexpression leads to hypertension-induced damage to the blood-brain barrier by reprogrammed macrophages.
French Abivax SA has raised 130m capital led by TCGX to accelerate Phase III testing of its ulcerative colitis candidate obefazimod extend its cashflow.
PVH Corp has joined fiber-to-fiber consortium that wants to make textile recycling sustainable by establishing standards for biorecycled textile fibre.
A UK Biobank study suggests that higher intake of free sugars is associated with a higher risk to develop cardiovascular disease, UK researchers report in BMC Medicine.